9 METERS BIOPHARMA INC (NMTR) Stock Price, Quote, News and Overview
NASDAQ:NMTR - Nasdaq - US6544052086 - Common Stock - Currency: USD
NMTR Quote, Performance and Key Statistics
0.0722
-0.05 (-42.97%)
The current stock price of NMTR is 0.0722 USD. In the past month the price decreased by -88.9%. In the past year, price decreased by -98.36%.
NMTR Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.8 | 836.73B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 28.22 | 402.13B | ||
| JNJ | JOHNSON & JOHNSON | 16.39 | 394.22B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.69 | 231.63B | ||
| MRK | MERCK & CO. INC. | 11.95 | 230.88B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.76 | 215.72B | ||
| PFE | PFIZER INC | 8.57 | 151.03B | ||
| SNY | SANOFI-ADR | 13.4 | 134.76B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 50.77 | 117.39B | ||
| GSK | GSK PLC-SPON ADR | 7.89 | 75.67B | ||
| ZTS | ZOETIS INC | 27.92 | 74.58B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 32 | 44.64B |
Related stock screener links
About NMTR
Company Profile
9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on unmet needs in gastroenterology. The company is headquartered in Raleigh, North Carolina and currently employs 10 full-time employees. The company went IPO on 2016-07-08. The firm is engaged in developing novel treatments for people with rare digestive diseases, gastrointestinal (GI) conditions with unmet needs, and debilitating disorders in which the biology of the gut is a contributing factor. The firm is developing vurolenatide, a proprietary long-acting GLP-1 agonist in Phase 3 development for short bowel syndrome as well as near clinical-stage assets including NM-136 for obesity disorders. The long-acting linker technology is designed specifically to address the gastric effects in SBS patients by slowing digestive transit time. Vurolenatide uses proprietary XTEN technology to extend the half-life of exenatide, potentially allowing for every other week dosing (Q2W). NM-136 is a long-acting, highly specific, humanized anti-GIP monoclonal antibody.
Company Info
9 METERS BIOPHARMA INC
4509 Creedmoor Road, Suite 600
Raleigh NORTH CAROLINA 27615 US
CEO: John Temperato
Employees: 10
Company Website: https://9meters.com/
Phone: 19192751933.0
9 METERS BIOPHARMA INC / NMTR FAQ
What is the stock price of 9 METERS BIOPHARMA INC today?
The current stock price of NMTR is 0.0722 USD. The price decreased by -42.97% in the last trading session.
What is the ticker symbol for 9 METERS BIOPHARMA INC stock?
The exchange symbol of 9 METERS BIOPHARMA INC is NMTR and it is listed on the Nasdaq exchange.
On which exchange is NMTR stock listed?
NMTR stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for 9 METERS BIOPHARMA INC stock?
11 analysts have analysed NMTR and the average price target is 10.58 USD. This implies a price increase of 14557.2% is expected in the next year compared to the current price of 0.0722. Check the 9 METERS BIOPHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is 9 METERS BIOPHARMA INC worth?
9 METERS BIOPHARMA INC (NMTR) has a market capitalization of 1.04M USD. This makes NMTR a Nano Cap stock.
How many employees does 9 METERS BIOPHARMA INC have?
9 METERS BIOPHARMA INC (NMTR) currently has 10 employees.
Should I buy 9 METERS BIOPHARMA INC (NMTR) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of NMTR, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of NMTR, evaluating the profitability, health, valuation and growth aspects
- 9 METERS BIOPHARMA INC (NMTR) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- 9 METERS BIOPHARMA INC (NMTR) Sales and EPS estimates to see what analysts future expectations are.
- 9 METERS BIOPHARMA INC (NMTR) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- 9 METERS BIOPHARMA INC (NMTR) Insider and Institutional Ownership to learn about the owners and their transactions.
- 9 METERS BIOPHARMA INC (NMTR) Stock Chart to make your own analysis
- 9 METERS BIOPHARMA INC (NMTR) Latest news and press-releases to stay up to date.
Does 9 METERS BIOPHARMA INC (NMTR) stock pay dividends?
NMTR does not pay a dividend.
When does 9 METERS BIOPHARMA INC (NMTR) report earnings?
9 METERS BIOPHARMA INC (NMTR) will report earnings on 2023-08-14, before the market open.
What is the Price/Earnings (PE) ratio of 9 METERS BIOPHARMA INC (NMTR)?
9 METERS BIOPHARMA INC (NMTR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.46).
NMTR Technical Analysis
NMTR Financial Highlights
Over the last trailing twelve months NMTR reported a non-GAAP Earnings per Share(EPS) of -3.46. The EPS decreased by -8.12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
NMTR Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to NMTR. The Buy consensus is the average rating of analysts ratings from 11 analysts.